Inherited and acquired alterations in development of breast cancer

Application of Clinical Genetics

Volumn 4, Issue , 2011, Pages 145-158

  Rizzolo, Piera ^a   Silvestri, Valentina ^a   Falchetti, Mario ^a   Ottini, Laura ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acquired alterations; Breast cancer; Epigenetics; Inherited susceptibility

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR BETA; MICRORNA; PROTEIN P53;

ARTICLE; ATM GENE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER SUSCEPTIBILITY; CHEK2 GENE; DNA METHYLATION; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EPIGENETICS; ESTROGEN RECEPTOR BETA GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HER2 GENE; HUMAN; MUTATIONAL ANALYSIS; MUTATOR GENE; ONCOGENE; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TP53 GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE;

EID: 84864383547     PISSN: 1178704X     EISSN: None     Source Type: Journal    
DOI: 10.2147/TACG.S13226     Document Type: Article

References (178)

1. Willems PG. Susceptibility genes in breast cancer: more is less? Clin Genet. 2007;72:493-496.
2. Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28:232-239.
3. Martin AM, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst. 2000;92:1126-1135.
4. Thompson D, Easton D. The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia. 2004;9:221-236.
5. Lee EY, Muller WJ. Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol. 2010;2:a003236.
6. Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 2009;462:1005-1010.
7. Esteller M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet. 2007;8:286-298.
8. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704-714.
9. Hirshfield KM, Rebbeck TR, Levine AJ. Germline mutations and polymorphisms in the origins of cancers in women. J Oncol. 2010. Epub 2010 Jan 10.
10. Borresen AL, Andersen TI, Garber J, et al. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res. 1992;52: 3234-3236.
11. Chen J, Lindblom P, Lindblom A. A study of the PTEN/MMAC1 gene in 136 breast cancer families. Hum Genet. 1998;102:124-125.
12. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med. 2003;348:2339-2347.
13. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet. 2008;40:17-22.
14. Nathanson KL, Wooster R, Weber BL. Breast cancer genetics: what we know and what we need. Nat Med. 2001;7:552-556.
15. Martin AM, Blackwood MA, Antin-Ozerkis D, et al. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J Clin Oncol. 2001;19: 2247-2253.
16. Liebens FP, Carly B, Pastijn A, Rozenberg S. Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer. 2007;43:238-257.
17. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676-689.
18. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
19. Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006; 24:863-871.
20. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480-1490.
21. Ottini L, Rizzolo P, Zanna I, et al. BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. Breast Cancer Res Treat. 2009;116:577-586.
22. Papi L, Putignano AL, Congregati C, et al. Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy. Breast Cancer Res Treat. 2009;117:497-504.
23. Durocher F, Shattuck-Eidens D, McClure M, et al. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet. 1996;5:835-842.
24. Dunning AM, Chiano M, Smith NR, et al. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet. 1997;6:285-289.
25. Qiu LX, Yao L, Xue K, et al. BRCA2 N372H polymorphism and breast cancer susceptibility: a meta-analysis involving 44,903 subjects. Breast Cancer Res Treat. 2010;123:487-490.
26. Palli D, Falchetti M, Masala G, et al. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based casecontrol study in Tuscany, Central Italy. BMC Cancer. 2007;7:170.
27. Thompson D, Easton D. Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001;68:410-419.
28. Thompson D, Easton D. Breast Cancer Linkage Consortium. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev. 2002;11:329-336.
29. Phelan CM, Kwan E, Jack E, et al. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. Hum Mutat. 2002;20:352-357.
30. Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 1995;11:198-200.
31. Gudmundsson J, Johannesdottir G, Arason A, et al. Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet. 1996;58: 749-756.
32. Thorlacius S, Olafsdottir G, Tryggvadottir L, et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996;13: 117-119.
33. Johannesdottir G, Gudmundsson J, Bergthorsson JT, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res. 1996;56:3663-3665.
34. Baudi F, Quaresima B, Grandinetti C, et al. Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. Hum Mutat. 2001;18:163-164.
35. Russo A, Calò V, Bruno L, et al. Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation? Breast Cancer Res Treat. 2009;113:67-70.
36. Caligo MA, Ghimenti C, Cipollini G, et al. BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations. Oncogene. 1996;13:1483-1488.
37. Sluiter MD, van Rensburg EJ. Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. Breast Cancer Res Treat. 2011;125:325-349.
38. Hansen TO, Jønson L, Albrechtsen A, Andersen MK, Ejlertsen B, Nielsen FC. Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families. Breast Cancer Res Treat. 2009;115:315-323.
39. Karhu R, Laurila E, Kallioniemi A, Syrjäkoski K. Large genomic BRCA2 rearrangements and male breast cancer. Cancer Detect Prev. 2006;30:530-534.
40. Woodward AM, Davis TA, Silva AG, Kirk JA, Leary JA; KConFab Investigators. Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families. J Med Genet. 2005;42:e31.
41. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295:1379-1388.
42. Wang T, Lerer I, Gueta Z, et al. A deletion/insertion mutation in the BRCA2 gene in a breast cancer family: a possible role of the Alu-polyA tail in the evolution of the deletion. Genes Chromosomes Cancer. 2001;31:91-95.
43. Tournier I, Paillerets BB, Sobol H, et al. Significant contribution of germline BRCA2 rearrangements in male breast cancer families. Cancer Res. 2004;64:8143-8147.
44. Gutiérrez-Enríquez S, de la Hoya M, Martínez-Bouzas C, et al. Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer. Breast Cancer es Treat. 2007;103:103-107.
45. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;3:55-59.
46. Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol. 2008;26:542-548.
47. Neuhausen S, Dunning A, Steele L, et al. Role of CHEK2(*)1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer. 2004;108:477-478.
48. Ohayon T, Gal I, Baruch RG, Szabo C, Friedman E. CHEK2(*)1100delC and male breast cancer risk in Israel. Int J Cancer. 2004;108:479-480.
49. Syrjäkoski K, Kuukasjärvi T, Auvinen A, Kallioniemi OP. CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer. 2004;108:475-476.
50. Falchetti M, Lupi R, Rizzolo P, et al. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat. 2008;110:161-167.
51. Martinez-Bouzas C, Beristain E, Guerra I, et al. CHEK2 1100delC is present in familial breast cancer cases of the Basque Country. Breast Cancer Res Treat. 2007;103:111-113.
52. Narod SA, Lynch HT. CHEK2 mutation and hereditary breast cancer. J Clin Oncol. 2007;25:6-7.
53. Caligo MA, Agata S, Aceto G, et al. The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. Hum Mutat. 2004;24:100-101.
54. Schutte M, Seal S, Barfoot R, et al. Breast Cancer Linkage Consortium. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet. 2003;72:1023-1028.
55. Bogdanova N, Enssen-Dubrowinskaja N, Feshchenko S, et al. Association of two mutations in the CHEK2 gene with breast cancer. Int J Cancer. 2005;116:263-266.
56. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 1987;316: 1289-1294.
57. Thompson D, Duedal S, Kirner J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005;97: 813-822.
58. Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006;38:873-875.
59. Levy-Lahad E. Fanconi anemia and breast cancer susceptibility meet again. Nat Genet. 2010;42:368-369.
60. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39:165-167.
61. Tischkowitz M, Xia B, Sabbaghian N, et al. Analysis of PALB2/ FANCN-associated breast cancer families. Proc Natl Acad Sci U S A. 2007;104:6788-6793.
62. Cao AY, Huang J, Hu Z, et al. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat. 2009;114:457-462.
63. Heikkinen T, Kärkkäinen H, Aaltonen K, et al. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res. 2009;15:3214-3222.
64. Papi L, Putignano AL, Congregati C, et al. A PALB2 germline mutation associated with hereditary breast cancer in Italy. Fam Cancer. 2010;9: 181-185.
65. Dansonka-Mieszkowska A, Kluska A, Moes J, et al. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Med Genet. 2010;11:20.
66. Sluiter M, Mew S, van Rensburg EJ. PALB2 sequence variants in young South African breast cancer patients. Fam Cancer. 2009;8:347-353.
67. García MJ, Fernández V, Osorio A, et al. Analysis of FANCB and FANCN/PALB2 Fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat. 2009;113: 545-551.
68. Balia C, Sensi E, Lombardi G, Roncella M, Bevilacqua G, Caligo MA. PALB2: a novel inactivating mutation in a Italian breast cancer family. Fam Cancer. 2010;9:531-536.
69. Ding YC, Steele L, Chu LH, et al. Germline mutations in PALB2 in African-American breast cancer cases. Breast Cancer Res Treat. 2011; 126:227-230.
70. Erkko H, Xia B, Nikkilä J, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446:316-319.
71. Foulkes WD, Ghadirian P, Akbari MR, et al. Identification of a novel truncating PALB2 mutation and analysis of its contribution to earlyonset breast cancer in French-Canadian women. Breast Cancer Res. 2007;9:R83.
72. Sauty de Chalon A, Teo Z, Park DJ, et al. Are PALB2 mutations associated with increased risk of male breast cancer? Breast Cancer Res Treat. 2010;121:253-255.
73. Silvestri V, Rizzolo P, Zanna I, et al. PALB2 mutations in male breast cancer: a population-based study in Central Italy. Breast Cancer Res Treat. 2010;122:299-301.
74. Adank MA, van Mil SE, Gille JJ, Waisfisz Q, Meijers-Heijboer H. PALB2 analysis in BRCA2-like families. Breast Cancer Res Treat. 2011;127:357-362.
75. Ding YC, Steele L, Kuan CJ, Greilac S, Neuhausen SL. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat. 2011;126:771-778.
76. Casadei S, Norquist BM, Walsh T, et al. Contribution to familial breast cancer of inherited mutations in the BRCA2-interacting protein PALB2. Cancer Res. 2011;71:2222-2229.
77. Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006;38:1239-1241.
78. Karppinen SM, Vuosku J, Heikkinen K, Allinen M, Winqvist R. No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families. Eur J Cancer. 2003;39:366-371.
79. Guénard F, Labrie Y, Ouellette G, et al. Mutational analysis of the breast cancer susceptibility gene BRIP1/BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families. J Hum Genet. 2008; 53:579-591.
80. Cao AY, Huang J, Hu Z, et al. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat. 2009;115:51-55.
81. Lewis AG, Flanagan J, Marsh A, et al. Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Res. 2005;7:R1005-R1016.
82. De Nicolo A, Tancredi M, Lombardi G, et al. A novel breast cancer associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. Clin Cancer Res. 2008;14:4672-4680.
83. Silvestri V, Rizzolo P, Falchetti M, et al. Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy. Breast Cancer Res Treat. 2011;126:539-543.
84. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010;42:410-414.
85. Akbari MR, Tonin P, Foulkes WD, Ghadirian P, Tischkowitz M, Narod SA. RAD51C germline mutations in breast and ovarian cancer patients. Breast Cancer Res. 2010;12:404.
86. Zheng Y, Zhang J, Hope K, Niu Q, Huo D, Olopade OI. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat. 2010; 124:857-861.
87. Silvestri V, Rizzolo P, Falchetti M, et al. Mutation screening of RAD51C in male breast cancer patients. Breast Cancer Res. 2011; 13:404.
88. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002;31:33-36.
89. Breast Cancer Association Consortium. Commonly studied singlenucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst. 2006; 98:1382-1396.
90. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447:1087-1093.
91. Cox A, Dunning AM, Garcia-Closas M, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet. 2007; 39:352-358.
92. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2008;40:703-706.
93. Thomas G, Jacobs KB, Kraft P, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet. 2009;41:579-584.
94. Dunning AM, Healey CS, Baynes C, et al. Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet. 2009; 18:1131-1139.
95. Turnbull C, Ahmed S, Morrison J, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet. 2010;42:504-507.
96. Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat Rev Cancer. 2010;10:353-361.
97. Antoniou AC, Spurdle AB, Sinilnikova OM, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008; 82:937-948.
98. Wasserman NF, Aneas I, Nobrega MA. An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. Genome Res. 2010;20:1191-197.
99. Ghoussaini M, Song H, Koessler T, et al. Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst. 2008;100:962-966.
100. Wokołorczyk D, Lubiński J, Narod SA, Cybulski C. Genetic heterogeneity of 8q24 region in susceptibility to cancer. J Natl Cancer Inst. 2009;101:278-279.
101. Wokolorczyk D, Gliniewicz B, Sikorski A, et al. A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer Res. 2008;68:9982-9986.
102. Bonifaci N, Górski B, Masojć B, et al. Exploring the link between germline and somatic genetic alterations in breast carcinogenesis. PLoS One. 2010;5:e14078.
103. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptorpositive breast cancer. Nat Genet. 2007;39:865-869.
104. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res. 2008;14: 8000-8009.
105. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318: 1108-1113.
106. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446:153-158.
107. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 2004;3:772-775.
108. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005;65:2554-2559.
109. Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat. 2006;96:91-95.
110. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res. 2007;13(2 Pt 1):408-414.
111. Jong YJ, Li LH, Tsou MH, et al. Chromosomal comparative genomic hybridization abnormalities in early- and late-onset human breast cancers: correlation with disease progression and TP53 mutations. Cancer Genet Cytogenet. 2004;148:55-65.
112. Langerød A, Zhao H, Borgan Ø, et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 2007;9:R30.
113. Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res. 2009;69:3625-3633.
114. Al-Kuraya K, Schraml P, Torhorst J, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 2004;64:8534-8540.
115. Sunami E, Shinozaki M, Sim MS, et al. Estrogen receptor and HER2/ neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res. 2008;10:R46.
116. Nana-Sinkam SP, Croce CM. Micro RNAs as therapeutic targets in cancer. Transl Res. 2011;157:216-225.
117. Lerebours F, Lidereau R. Molecular alterations in sporadic breast cancer. Crit Rev Oncol Hematol. 2002;44:121-141.
118. Bell DW. Our changing view of the genomic landscape of cancer. J Pathol. 2010;220:231-243.
119. Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466: 869-873.
120. Arnold JM, Choong DY, Thompson ER, et al. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors. Breast Cancer Res Treat. 2010;119:491-496.
121. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64: 7678-7681.
122. Buttitta F, Felicioni L, Barassi F, et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol. 2006;208:350-355.
123. Dunlap J, Le C, Shukla A, et al. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat. 2010;120:409-418.
124. Benvenuti S, Frattini M, Arena S, et al. PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat. 2008; 29:284-288.
125. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 2005;5:921-929.
126. Børresen-Dale AL. TP53 and breast cancer. Hum Mutat. 2003;21: 292-300.
127. Olivier M, Hainaut P. TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Semin Cancer Biol. 2001;11:353-360.
128. McKinzie PB, Delongchamp RR, Heflich RH, Parsons BL. Prospects for applying genotypic selection of somatic oncomutation to chemical risk assessment. Mutat Res. 2001;489: 47-78.
129. Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene. 2006;25:1602-1611.
130. Damin AP, Frazzon AP, Damin DC, et al. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev. 2006;30:523-529.
131. Khadang B, Fattahi MJ, Talei A, Dehaghani AS, Ghaderi A. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet. 2007;173:38-42.
132. Osorio A, Martínez-Delgado B, Pollán M, et al. A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers. Hum Mutat. 2006;27:242-248.
133. Martin AM, Kanetsky PA, Amirimani B, et al. Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1? J Med Genet. 2003;40:e34.
134. Venables JP, Klinck R, Bramard A, et al. Identification of alternative splicing markers for breast cancer. Cancer Res. 2008;68: 9525-9531.
135. Watson PM, Watson DK. Alternative splicing in prostate and breast cancer. The Open Cancer Journal. 2010;3:62-76.
136. Orban TI, Olah E. Emerging roles of BRCA1 alternative splicing. Mol Pathol. 2003;56:191-197.
137. Castiglioni F, Tagliabue E, Campiglio M, Pupa SM, Balsari A, Ménard S. Role of exon-16-deleted HER2 in breast carcinomas. Endocr Relat Cancer. 2006;13:221-232.
138. André F, Michiels S, Dessen P, et al. Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol. 2009;10:381-390.
139. LaVoie HA, DeSimone DC, Gillio-Meina C, Hui YY. Cloning and characterization of porcine ovarian estrogen receptor β-isoforms. Biol Reprod. 2002;66:616-623.
140. Kwong KY, Hung M. A novel splice variant of HER2 with increased transformation activity. Mol Carcinog. 1998;23:62-68.
141. Rodriguez C, Hughes-Davies L, Vallès H, et al. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Clin Cancer Res. 2004;10:5785-5791.
142. Ciampa A, Xu B, Ayata G, et al. HER-2 status in breast cancer: correlation of gene amplification by FISH with immuno histo chemistry expression using advanced cellular imaging system. Appl Immunohistochem Mol Morphol. 2006;14:132-137.
143. Vanden Bempt I, Drijkoningen M, De Wolf-Peeters C. The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity. Curr Opin Oncol. 2007;19: 552-557.
144. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998;16:413-428.
145. Francis G, Beadle G, Thomas S, Mengersen K, Stein S. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome. Pathology. 2006;38: 391-398.
146. Stratford AL, Fry CJ, Desilets C, et al. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res. 2008;10:R99.
147. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat. 2002;71:67-75.
148. Uberall I, Kolár Z, Trojanec R, Berkovcová J, Hajdúch M. The status and role of ErbB receptors in human cancer. Exp Mol Pathol. 2008;84:79-89.
149. Toyama T, Yamashita H, Kondo N, et al. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer. 2008;8:309.
150. Chen Y. MYC in breast tumor progression. Expert Rev Anticancer Ther. 2008;8:1689-1698.
151. Holst F, Stahl PR, Ruiz C, et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet. 2007;39: 655-660.
152. Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast. 2006;15: 718-727.
153. Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C. Cyclin gene amplification and over expression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin Einovarian tumors. Int J Cancer. 1996;69:247-253.
154. Bärlund M, Monni O, Kononen J, et al. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res. 2000;60:5340-5344.
155. Kirkegaard T, Nielsen KV, Jensen LB, et al. Genetic alterations of CCND1 and EMSY in breast cancers. Histopathology. 2008;52: 698-705.
156. Tan DS, Marchiò C, Reis-Filho JS. Hereditary breast cancer: from molecular pathology to tailored therapies. J Clin Pathol. 2008;61: 1073-1082.
157. Tommasi S, Mangia A, Iannelli G, et al. Gene copy number variation in male breast cancer by aCGH. Anal Cell Pathol (Amst). 2010;33: 113-119.
158. Fonseca RR, Tomás AR, André S, Soares J. Evaluation of ERBB2 gene status and chromosome 17 anomalies in male breast cancer. Am J Surg Pathol. 2006;30:1292-1298.
159. Bärlund M, Kuukasjärvi T, Syrjäkoski K, Auvinen A, Kallioniemi A. Frequent amplification and overexpression of CCND1 in male breast cancer. Int J Cancer. 2004;111:968-971.
160. Dworkin AM, Huang THM, Ewart Toland A. Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol. 2009;19:165-171.
161. Jovanovica J, Anders Rønnebergb J, Tost J, Kristensena V. The epigenetics of breast cancer. Mol Oncol. 2010;4:242-254.
162. Lapidus R, Ferguson AT, Ottaviano YL, et al. Methylation of estrogen and progesterone receptor gene 50 CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res. 1996;2:805-810.
163. Bae YK, Brown A, Garrett E, et al. Hypermethylation in histologically distinct classes of breast cancer. Clin Cancer Res. 2004;10: 5998-6005.
164. Fackler MJ, McVeigh M, Evron E, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Cancer. 2003;107:970-975.
165. Li S, Rong M, Iacopetta B. DNA hyper methylation in breast cancer and its association with clinicopathological features. Cancer Lett. 2006;237:272-280.
166. Feng W, Shen L, Wen S, et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res. 2007;9:R57.
167. Parrella P, Poeta ML, Gallo AP, et al. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res. 2004;10:5349-5354.
168. Widschwendter M, Siegmund KD, Muller HM, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 2004;64:3807-3813.
169. Shenouda SK, Alahari SK. Micro RNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009;28:369-378.
170. Iorio MV, Ferracin M, Liu CG, et al. Micro RNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065-7070.
171. Shi M, Guo N. Micro RNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev. 2009;35:328-334.
172. Png KJ, Yoshida M, Zhang XH, et al. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev. 2011;25:226-231.
173. Fassan M, Baffa R, Palazzo JP, et al. Micro RNA expression profiling of male breast cancer. Breast Cancer Res. 2009;11:R58.
174. Lehmann U, Streichert T, Otto B, et al. Identification of differentially expressed microRNAs in human male breast cancer. BMC Cancer. 2010;10:109.
175. Sempere LF, Christensen M, Silahtaroglu A, et al. Altered micro RNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007;67:11612-11620.
176. Yan LX, Huang XF, Shao Q, et al. Micro RNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14: 2348-2360.
177. Ottini L, Capalbo C, Rizzolo P, et al. HER2-positive male breast cancer: an update. Breast Cancer: Targets and Therapy. 2010;2:45-58.
178. Saxena R, Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. Med Res Rev. October 25, 2010. [Epub ahead of print].